Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
CDK2 inhibition produces a persistent population of polyploid cancer cells
Liliya Tyutyunyk-Massey, Zibo Chen, Xiuxia Liu, Masanori Kawakami, Adam Harned, Yeap Ng, Brian Luke, Samuel C. Okpechi, Blessing Ogunlade, Yair Alfaro, Roberto Weigert, Kedar Narayan, Xi Liu, Ethan Dmitrovsky
Liliya Tyutyunyk-Massey, Zibo Chen, Xiuxia Liu, Masanori Kawakami, Adam Harned, Yeap Ng, Brian Luke, Samuel C. Okpechi, Blessing Ogunlade, Yair Alfaro, Roberto Weigert, Kedar Narayan, Xi Liu, Ethan Dmitrovsky
View: Text | PDF
Research Article Oncology Therapeutics

CDK2 inhibition produces a persistent population of polyploid cancer cells

  • Text
  • PDF
Abstract

Aneuploidy, a cancer hallmark, drives chromosomal instability, drug resistance, and clinically aggressive tumors. Cyclin-dependent kinase 2 (CDK2) antagonism with independent inhibitors or CDK2 knockdown triggered anaphase catastrophe. This disrupts supernumerary centrosome clustering, causing multipolar division and apoptosis. Time-lapse fluorescence microscopy of fluorescent ubiquitination-based cell cycle indicator (FUCCI) cell cycle probes transduced into aneuploid lung cancer cells revealed distinct fates of bipolar and polyploid cells after CDK2 inhibition. Apoptosis occurred in multipolar progeny but was repressed in persistent polyploid cancer cells. RNA-Seq analyses after CDK2 inhibition of 4N versus 2N lung cancer cells were enriched for CDK1 pathway and KIF family members. The Cancer Genome Atlas (TCGA) analysis of lung cancers indicated that CDK1 and KIF family member overexpression was associated with an unfavorable survival. Intravital microscopy of transplanted lung cancer cells in mice extended findings from the in vitro to in vivo settings. CDK2 inhibition of tumor-bearing mice produced polyploid cancer cells in vivo. These cancer cells were resistant to apoptosis and proliferated despite CDK2 inhibition. In contrast, polyploid populations were rarely detected in CDK2-inhibited human alveolar epithelial cells. These findings are translationally relevant. Combined targeting of CDK2 with CDK1 or kinesin family member antagonists should eliminate polyploid cancer cells, promote apoptosis, and augment antineoplastic effects.

Authors

Liliya Tyutyunyk-Massey, Zibo Chen, Xiuxia Liu, Masanori Kawakami, Adam Harned, Yeap Ng, Brian Luke, Samuel C. Okpechi, Blessing Ogunlade, Yair Alfaro, Roberto Weigert, Kedar Narayan, Xi Liu, Ethan Dmitrovsky

×

Figure 6

Overall survival of patients with lung cancer.

Options: View larger image (or click on image) Download as PowerPoint
Overall survival of patients with lung cancer.
Overall survival of patie...
Overall survival of patients with lung cancer having these differentially expressed genes (CDK1, PLK1, AURKA, KIFC1, KIF2C and KIF22) in polyploid versus diploid cancer cells after CYC065 but not vehicle-treatments within the displayed lung adenocarcinoma cohort (566 patients) as part of the PanCancer Atlas in The Cancer Genome Atlas (TCGA). (A) Overexpression of CDK1, PLK1, AURKA, KIFC1, KIF2C or KIF22 was significantly associated with a high aneuploidy score. The Wilcoxon test was used to compare aneuploidy scores of the examined patients with P values below 0.05 deemed statistically significant. (B) CDK1 expression was statistically significantly associated with the expression profiles of PLK1, AURKA, KIFC1, and KIF2C but weakly for KIF22. The Spearman’s rank correlation coefficient was used to test the indicated associations, with P values below 0.05 deemed statistically significant. (C) Overexpression profiles of CDK1, PLK1, AURKA, KIFC1, and KIF2C indicate an unfavorable overall survival of patients with lung cancer. KIF22 expression in lung cancer did not affect overall survival. (D) The combined overexpression profiles of CDK1 + KIFC1, CDK1 + KIF2C, CDK1 + KIF22, PLK1 + KIFC1, PLK1 + KIF2C, and AURKA + KIF22 were associated with an unfavorable overall survival in the examined patients with lung cancer. Survival analysis for B and D was performed using the Kaplan-Meier method using the log-rank test, with a P value below 0.05 deemed statistically significant.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts